



Prior Authorization Request Form for Botulinum Toxins

FAX this completed form to (844) 205-3386

OR Mail requests to: Pharmacy Department | 5 River Park Place East, Suite 210 | Fresno, CA 93720

OR Prior authorization may be completed at <https://www.covermyeds.com/main/prior-authorization-forms/>

I. PROVIDER INFORMATION		II. MEMBER INFORMATION	
Prescriber Name:		Member Name:	
Prescriber Specialty:		Identification #:	
NPI:		Group #:	
Office Contact Name:		Date of Birth:	
Fax #:		Medication Allergies:	
Phone #:			
III. DRUG INFORMATION (One drug request per form)			
Drug name and strength:		Dosage Interval (sig):	Qty. Requested:
Please list treatment plan including proposed injection sites and dose that will be injected into each site:			
Dates of previous injections:			
IV. REQUIRED DOCUMENTATION (Detailed medical record documentation demonstrating evidence for each item must be submitted with prior authorization request)			
Specify diagnosis & diagnosis code relevant to this request:		Dx/Dx Code: _____	
Does the member have a history of contraindication to the prescribed medication?		<input type="checkbox"/> Yes <input type="checkbox"/> No	
Requests for all non-preferred medications: Does the member have a history of trial and failure of or contraindication or intolerance to the preferred Botulinum Toxins? Refer to https://papdl.com/preferred-drug-list for a list of preferred and non-preferred medications in this class.		<input type="checkbox"/> Yes Medication Taken Previously (start and end date and dose): _____ <input type="checkbox"/> No _____	
<input type="checkbox"/> If requesting for daily quantity exceeding daily limit (Refer to https://www.dhs.pa.gov/providers/Pharmacy-Services/Pages/Quantity-Limits-and-Daily-Dose-Limits.aspx), please provide supporting information: _____			
SUBMIT MEDICAL RECORD INFORMATION FOR EACH APPLICABLE ITEM.			
CHRONIC SPASTICITY:			
<input type="checkbox"/> Member has documented spasticity that: <input type="checkbox"/> Interferes with daily living, evidenced by: _____ <input type="checkbox"/> Is expected to result in joint contracture with future growth: _____			
<input type="checkbox"/> For member age 18 or older, has documented therapeutic failure, contraindication or intolerance to at least 1 oral medication for spasticity (medication, start date and end date): _____			
<input type="checkbox"/> If member has developed contractures, they have been considered for surgical intervention			
<input type="checkbox"/> Botulinum toxin is requested to: <input type="checkbox"/> Enhance function: _____ <input type="checkbox"/> Allow for additional therapeutic modalities: _____			
<input type="checkbox"/> Will use botulinum toxin in conjunction with other appropriate therapeutic modalities (physical therapy, occupational therapy, gradual splinting, etc): _____			

AXILLARY HYPERHIDROSIS:

- ☐ Documented history of therapeutic failure, contraindication or intolerance to a topical agent (Aluminum Chloride 20%): (medication, start date and end date) _____

CHRONIC MIGRAINE:

- ☐ Member has a history of chronic migraine headache not attributed to other causes including medication overuse:
☐ Number of headache days per month: _____
- ☐ If not prescribed by one of the following specialist neurologist or headache specialist (certified in headache medicine but the United Council for Neurological Subspecialties (UCNS)), please indicate a specialist consulted: _____
- ☐ Documented history of therapeutic failure, contraindication or intolerance to at least 1 migraine preventative medication from following 2 of the following classes: (medication, start date and end date)
☐ Beta-Blocker (e.g. metoprolol, propranolol, timolol): _____
☐ Antidepressant (e.g. amitriptyline, venlafaxine): _____
☐ Anticonvulsant (e.g. topiramate, valproic acid, divalproex): _____

URINARY INCONTINENCE DUE TO DETRUSOR OVERACTIVITY ASSOCIATED WITH NEUROLOGIC CONDITION:

- ☐ Documented history of therapeutic failure, contraindication or intolerance to at least 1 anticholinergic medication used to treat urinary incontinence: (medication, start date and end date) _____

OVERACTIVE BLADDER:

- ☐ Member has overactive bladder with symptoms of urge urinary incontinence, urgency and frequency
- ☐ Documented history of therapeutic failure, contraindication or intolerance to at least 2 agents (e.g., antimuscarinics or beta-3 adrenergic agonists) used to treat overactive bladder: (medication, start date and end date) _____

RENEWAL REQUEST:

- ☐ Request exceeds the recommended FDA dosing and duration of therapy:
☐ Previous treatment was well tolerated but inadequate
☐ Medical literature supports more frequent dosing intervals as safe and effective for the diagnosis and requested dose
- ☐ Request is consistent with the recommended FDA dosing and duration of therapy:
☐ Previous treatment was well tolerated and the member showed a positive clinical response
☐ Symptoms returned to such a degree that repeat injection is required

IV. ADDITIONAL RATIONALE FOR REQUEST / PERTINENT CLINICAL INFORMATION :

Appropriate clinical information to support the request on the basis of medical necessity must be submitted.

Provider Signature:

Date:

Pharmacy Department will respond via fax or phone within 24 hours.

Requests for prior authorization (PA) requests must include member name, ID#, and drug name. Please include lab reports with requests when appropriate (e.g., Culture and Sensitivity; Hemoglobin A1C; Serum Creatinine; CD4; Hematocrit; WBC, etc.)